Search

A new study suggests that having two copies of the APOE4 gene may be the genetic cause of up to one fifth of all Alzheimer's disease cases. The study found that individuals with two copies of the APOE4 gene had higher levels of Alzheimer's disease biomarkers and developed symptoms of the disease by age 65. The findings indicate that APOE4 may not just be a risk factor for Alzheimer's disease, but also a distinct genetic form of the disease. The study recommends more widespread testing for APOE4 and may lead to advancements in drug development and Alzheimer's disease prevention. However, some experts urge caution in interpreting the results and emphasize that having two copies of the APOE4 gene does not guarantee the development of Alzheimer's disease. [Extracted from the article]

The article offers the author's insights on potential use of blood tests to determine the risk of alzheimer's disease and other brain illness. Topics discussed include the blog of philanthropist Bill Gates on his calls for new method to combat dementia through an accessible diagnostic like blood test, the link of Apolipoprotein E (ApoE4) gene variant to alzheimer as well as the social stigma related to the disease, and the creation of website ApoE4.info. led by Julie Gregory.

The article discusses research on changes in the brain associated with Alzheimer's disease that can be seen as early as childhood in people with heightened genetic risk. It references a study by Rebecca Knickmeyer et al, published in the journal "Neurology." Topics covered include the symptoms of Alzheimer's, the size of the hippocampus among those with the e4 variant of apolipoprotein E and the assessment of the cognitive test scores of the young people.

The article offers news briefs related to the health care industry as of August 18, 2014. The World Health Organization has approved the use of unproven drugs to address the Ebola virus outbreak in West Africa. The stocks of pharmaceutical firm Cerulean Pharma Inc. has increased by 40% from $1.45 to $5.04 due to its outstanding financial performance. A case study found that a man without apolipoprotein E in his body has not showed any signs of Alzheimer's disease and is cognitively normal.

The article focuses on a study by doctor Mary Malloy and colleagues at the University of California, San Francisco regarding the potential of apolipoprotein E (APOE) to treat Alzheimer's disease.

The article offers information on a study conducted to evaluate the role played by the gene apolipoprotein E (APOE) in Alzheimer's disease. In the study, called Reveal, people who have a close relative with Alzheimer's are told their own APOE status and their vulnerability to the disease. Robert C. Green, director of the study and a professor at Boston University, informed that disclosure of APOE status to people developed temporary distress in them.

Reports on a study which suggested that a detail of the structure of the Apo E gene is also linked to Alzheimer's disease, regardless of whether it is in the E-4 variant or another type. Number of variants the gene comes in; Reporting of the findings in the January 1998 issue of `Nature Genetics'; What was found when scientists looked in a part of the gene that regulates the gene's activity; Number of copies of the Ape E gene inherited by people; Further details on the study.

Reports on blood tests done at Rockefeller University which may predict when a person might die. The test identifying a protein produced by a gene known as apolipoprotein E (apo E); Researchers' assertion that apo E is rapidly emerging as the first-found of a set of mysterious genes that roughly determine how long a person will live; Three versions of the apo E gene and its protein.

Reveals that African-Americans and Hispanics have a higher risk of Alzheimer's disease regardless of its chance of carrying the apolipoprotein-E gene, according to a study by researchers from Columbia University College of Physicians and Surgeons. Details on the study published in the American Medical Association about the disease; How the study was conducted; Important point highlighted by the research, according to Dr. Richard Mayeux, senior investigator.